Next Article in Journal
New Enzyme-Inhibitory Triterpenoid from Marine Macro Brown Alga Padina boergesenii Allender & Kraft
Previous Article in Journal
Acknowledgement to Reviewers of Marine Drugs in 2016
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview

Marine Antibody–Drug Conjugates: Design Strategies and Research Progress

Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai 200433, China
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 210009, China
Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China
Authors to whom correspondence should be addressed.
These authors contribute equally to this paper.
Academic Editor: Peer B. Jacobson
Mar. Drugs 2017, 15(1), 18;
Received: 26 October 2016 / Revised: 30 December 2016 / Accepted: 4 January 2017 / Published: 13 January 2017
PDF [7774 KB, uploaded 13 January 2017]


Antibody–drug conjugates (ADCs), constructed with monoclonal antibodies (mAbs), linkers, and natural cytotoxins, are innovative drugs developed for oncotherapy. Owing to the distinctive advantages of both chemotherapy drugs and antibody drugs, ADCs have obtained enormous success during the past several years. The development of highly specific antibodies, novel marine toxins’ applications, and innovative linker technologies all accelerate the rapid R&D of ADCs. Meanwhile, some challenges remain to be solved for future ADCs. For instance, varieties of site-specific conjugation have been proposed for solving the inhomogeneity of DARs (Drug Antibody Ratios). In this review, the usages of various natural toxins, especially marine cytotoxins, and the development strategies for ADCs in the past decade are summarized. Representative ADCs with marine cytotoxins in the pipeline are introduced and characterized with their new features, while perspective comments for future ADCs are proposed. View Full-Text
Keywords: marine toxins; antibody–drug conjugates; monoclonal antibody; targeted therapy marine toxins; antibody–drug conjugates; monoclonal antibody; targeted therapy

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Wang, Y.-J.; Li, Y.-Y.; Liu, X.-Y.; Lu, X.-L.; Cao, X.; Jiao, B.-H. Marine Antibody–Drug Conjugates: Design Strategies and Research Progress. Mar. Drugs 2017, 15, 18.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top